CAS No: 218600-53-4
|Molecular Weight:||505.69 g/mol|
|Assay/Purity:||Typically NLT 98%|
|IUPAC Name:||Methyl 2-cyano-3,12-dioxooleana-1,9(11)dien-28-oate|
Bardoxolone methyl News:
Bardoxolone Methyl 218600-53-4, an Antioxidant Inflammation Modulator, is currently in clinical trials as a potential once a day treatment for those patients suffering from Chronic Kidney Disease (CKD). Developed by Reata Pharmaceuticals, Inc. in partnership with Abbott Laboratories and Kyowa Hakko Kirin, this drug will treat people suffering from CKD due to conditions such as Type 2 Diabetes Mellitus. Both oxidative stress and inflammation occur as a result of CKD, and Bardoxolone Methyl acts as an agent to activate the Nrf2 pathway, thus helping to preserve and aid kidney function in affected patients.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1).
Any patent infringement and resulting liability is solely at buyer risk.